Antipsychotic News and Research

RSS

Antipsychotics are medicines used to treat the symptoms of mental disorders such as schizophrenia, depression, bipolar disorder (sometimes called manic-depressive illness), anxiety disorders, and attention deficit-hyperactivity disorder (ADHD). Sometimes medications are used with other treatments such as psychotherapy.

Awards showcase Australia’s promising future in bio-sciences

The six state winners of the AusBiotech/GSK Student Excellence Awards, announced today, will next week compete for the national biosciences research award at AusBiotech 2011.

10 Oct 2011

UCLA scientists create mouse model for autism

UCLA scientists have created a mouse model for autism that opens a window into the biological mechanisms that underlie the disease and offers a promising way to test new treatment approaches.

30 Sep 2011

New report finds little evidence to support off-label use of atypical antipsychotics

There is little evidence to support the use of atypical antipsychotic drugs for some treatments other than their officially approved purposes, even though many clinicians continue to commonly prescribe these drugs for so-called "off label" uses, according to a new report from the U.S. Department of Health and Human Services' (HHS) Agency for Healthcare Research and Quality.

29 Sep 2011

Benefits and harms vary among atypical antipsychotics for off-label use

A review of previous studies suggests that even though atypical antipsychotic medications are commonly used for off-label conditions such as behavioral symptoms of dementia, anxiety, and obsessive-compulsive disorder, these medications are effective for only a few off-label conditions, and that the benefits and harms of these medications for these uses vary, according to an article in the September 28 issue of JAMA.

28 Sep 2011

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

BioLineRx, a biopharmaceutical development company, today announced that data from the successfully completed Phase IIb EAGLE study of BL-1020, a first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented at the 3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany.

28 Sep 2011

Humour therapy as effective as antipsychotic drugs in managing agitation in dementia patients

Humour therapy is as effective as widely used antipsychotic drugs in managing agitation in patients with dementia - and avoids serious drug side effects, a new study shows.

22 Sep 2011

Humour as effective as medication in treating agitation in dementia, research shows

...

18 Sep 2011

New report finds improvements in hospital performance

Meanwhile, Reuters reports on the quality of weekend care at stroke centers and nursing homes are trying to reduce their use of powerful antipsychotic drugs for patients with dementia.

16 Sep 2011

First Edition: September 15, 2011

In today's news, reports about what might be included in President Obama's detailed plan to tame the federal federal budget. Here's a hint: Social Security changes are unlikely, but what about Medicare?

15 Sep 2011

Researchers discover several chemical compounds against human prion diseases

In a new study NYU School of Medicine researchers report that they have found several chemical compounds, including an antidepressant, that have powerful effects against brain-destroying prion infections in mice, opening the door to potential treatments for human prion diseases.

15 Sep 2011

Simple pain relievers a better alternative to antipsychotic medications for dementia patients

Many dementia patients are being treated with antipsychotic medications, but a new study shows that simple pain relievers may be a better alternative.

8 Sep 2011

Mental health problems ail nearly half of all Americans: Report

According to a new government report about half of Americans will experience some form of mental health problem at some point in their life. The report stresses that more must be done to help the population with mental health problems.

6 Sep 2011

Researchers discover how antipsychotic drugs manage symptoms of schizophrenia

The classic symptoms of schizophrenia - paranoia, hallucinations, the inability to function socially-can be managed with antipsychotic drugs. But exactly how these drugs work has long been a mystery.

25 Aug 2011

Health Canada accepts Sunovion Pharmaceuticals Canada's lurasidone NDS for review

Sunovion Pharmaceuticals Canada Inc., formerly Sepracor Pharmaceuticals, Inc., today announced that the New Drug Submission (NDS) for Lurasidone HCl, for the treatment of adult patients with schizophrenia has been accepted for review by Health Canada. The NDS was submitted to Health Canada in June 2011 and will receive a standard review.

24 Aug 2011

FDA accepts Alexza ADASUVE NDA, assigns PDUFA action date

Alexza Pharmaceuticals, Inc. announced today that the U.S. Food & Drug Administration (FDA) has accepted the ADASUVE New Drug Application (NDA) as a complete, class 2 response to the FDA's action letter, with an indicated Prescription Drug User Fee Act (PDUFA) goal date of February 4, 2012.

20 Aug 2011

New tool can identify patients at high risk of venous thromboembolism

A new risk prediction tool can identify patients at high risk of serious blood clots (known as venous thromboembolism) who might need preventative treatment, says a study published on bmj.com today.

17 Aug 2011

Patients receive inadequate medical monitoring for prescribed drugs in psychiatric settings

New research from the University of Leicester demonstrates that psychiatrists are not offering adequate checks for metabolic complications that are common in patients with mental ill health - especially those prescribed antipsychotic medication.

10 Aug 2011

New preclinical approach can guide more efficient drug development for brain-related conditions

The development of drugs for brain-related conditions is not an efficient process; only 8% of candidate drugs that enter clinical trials gain FDA approval. A key reason for this low success rate is a lack of preclinical tests that accurately predict drug efficacy and detect unwanted side effects.

9 Aug 2011

Risperidone does not appear to reduce military-related PTSD symptoms

Patients with military-related, chronic posttraumatic stress disorder (PTSD) and symptoms that were not improved with use of an antidepressant medication did not experience a reduction in PTSD symptoms with use of the antipsychotic medication risperidone, according to a study in the August 3 issue of JAMA, a theme issue on violence and human rights.

3 Aug 2011

Post-traumatic stress disorder drug risperidone not working: Study

According to a new study a medication commonly used to treat post-traumatic stress disorder in combat veterans may not be effective in reducing overall PTSD severity.